The present invention relates generally to luer activated devices or valves that allow for the bi-directional transfer of fluids to and from medical fluid flow systems.
Luer activated devices (LAD) or valves (LAV) are commonly used in association with medical fluid containers and medical fluid flow systems that are connected to patients or other subjects undergoing diagnostic, therapeutic or other medical procedures. A LAD can be attached to or part of a fluid container or a medical fluid flow system to simplify the addition of fluids to or withdrawal of fluids from the fluid flow system.
Within the medical field there are a wide variety of medical fluid flow systems, serving a variety of functions. One of the more common uses of LADs are in association with fluid flow systems that are used for the intravenous administration of fluids, such as saline, antibiotics, or any number of other medically-related fluids, to a patient. These flow systems are commonly referred to as intravenous or “IV” fluid administration sets, and use plastic tubing to connect a phlebotomized subject to one or more medical fluid sources, such as intravenous solution or medicament containers.
Typically, such intravenous administration sets include one or more LADs providing needless access to the fluid flow path to allow fluid to be added to or withdrawn from the IV tubing. The absence of a needle for injecting or withdrawing fluid has the important advantage of reducing the incidence of needle stick injuries to medical personnel. A LAD typically includes a tapered female luer component, such as the inlet into a valve housing, that accepts and mates with a tapered male luer of a medical infusion or aspiration device, such as a needleless syringe or a administration set tubing brand.
There are certain characteristics and qualities of LADs that are highly desirable. For example, the LAD should provide a sufficient microbial barrier for the full service life of the valve. It is desirable that the microbial barrier be conducive to the application of standard aseptic techniques preformed by clinicians during the use of the device. For example, the geometry of the LAD should be such that it is easily swabbable and reduces the potential of entrapping particulates or contaminants that cannot be cleanly swabbed clear prior to use.
Furthermore, it is highly desirable that the LAD be substantially devoid of any interstitial space or any other “dead space” that cannot be flushed, or that such interstitial space be physically isolated from the fluid flow path. Such interstitial space has the potential of providing an environment for undesired microbial growth. In addition, the LAD should have a geometry that allows it to be sufficiently flushed so as to clear the dynamic fluid path and adjacent areas of residual blood or intravenous fluids to prevent undesired clotting or microbial growth.
LAD's are commonly used with intravenous catheters that provide access to a patient's vascular system. In such systems, another desirable feature of a LAD is minimal displacement of fluid during insertion and removal of the male luer. In certain situations, it is preferable that the LAD be a neutral/neutral device in that there is zero or only a very slight displacement of fluid during both insertion and removal of the male luer. In other situations it can be desirable for the LAD to produce a positive displacement of fluid from the valve housing during the removal of the male luer. The LAD also preferably prevents blood reflux into the catheter. Reflux is known to reduce the efficiency of the catheter and contribute to catheter clotting.
In most situations it is preferred that the LAD be dimensioned to be completely activated by a wide range of ISO compliant male luer lock adaptors. However, there may be some instances when the LAD may be designed to be activated by a male luer connector that is not ISO complaint or is a male luer slip connector. Another desirable characteristic of a LAD is the ability of the LAD to seal against pressure contained within a fluid system to which the LAD is connected. For example, it is desirable to be leak resistance to positive pressures ranging from 10 to 45 psi and to negative pressures or vacuum from 1 to 5 psi. The LAD also preferably has a geometry that allows for easy priming and flushing that does not require any additional manipulations to remove residual air bubbles from the tubing system.
These and other desirable characteristics, which may be used separately or in various combinations, are preferably present over the full service life of the valve. When used in connection with an IV set or catheter, the LAD may go through many connections and disconnections. It is desirable that the life of a LAD last through upwards to about 100 connections and disconnections or 96 hours of dwell time.
As described more fully below, the fluid access devices of the present invention provide important advances in the safe and efficient administration or withdrawal of medical fluids to or from a fluid flow system.
In accordance with one aspect of the present invention, a luer activated medical valve for the bi-directional transfer of fluid therethrough is provided with a valve housing having an inlet adapted to receive a male luer, an outlet, and a flow path defined therebetween. A valve element is received within the inlet of the valve housing and includes a resealable aperture adapted to receive a male luer to allow fluid to be transferred between the male luer and the flow path. In accordance with one aspect of this invention, when the male luer is inserted or removed from the aperture, there is substantially no fluid displacement from or into the valve housing.
Turning now to a more detailed description of the various embodiments of the present invention illustrated in the attached drawings, of which:
The embodiments disclosed herein are for the purpose of providing the required description of the present invention. These embodiment, however, are exemplary of the invention, which may be embodied in various forms. Therefore, specific details disclosed herein are not to be interpreted as limiting the invention as defined in the accompanying claims.
The outlet 20 is adapted to be connected to any of a number of fluid flow systems, so the exact configuration of the outlet 20 will vary according to the nature of the fluid flow system to which it is to be connected. For example, the illustrated outlet 20 is suitable for use in connecting the valve 10 to an IV administrative tubing set (not illustrated). In the embodiment of
The inlet 18 is adapted to receive a male connector such as a standard male luer 19 according to known structure and operation. The inlet 18 and male luer 19 preferably conform to ISO and/or ANSI standards. The male luer is generally tubular and preferably has a substantially smooth outer surface which is typically slightly tapered. The inlet 18 may include external threads 18a, in which case a portion of the connecting luer may be surrounded by a collar or skirt member (not illustrated) having internal threads adapted to removably lock the male luer to the inlet 18. Other attachment mechanisms, such frictional engagement with a tapered luer slip fit 19 may also be incorporated into LAD's according to the present invention.
To control flow through the housing 12, a valve system or element 28 is provided with a deformable upper seal or septum 30 defining a normally closed resealable first aperture 32 (preferably but not exclusively in the form of a slit) therethrough. The upper seal 30 is fixedly mounted to normally block and seal the inlet 18. A hollow blunt extension 34 extends downwardly from the upper seal 30 and communicates with the first aperture 32. Preferably, the extension 34 is comprised of a generally tubular portion 36, a generally conical or tapered portion 38, and a lower seal or septum portion 40 defining a generally blunt nose end with a second normally closed resealable aperture 42 therethrough. An internal chamber 44 is defined by the valve element 28 and connects the apertures 32 and 42. The chamber 44 is normally closed or isolated from the flow path 22 when the second aperture 42 is in a closed condition. The valve element 28 thus acts as a microbial barrier between the internal fluid flow path 22 of the LAD 10 and the atmosphere and substantially prevents fluid displacement when a luer is inserted into or removed from the LAD 10, as will be described in greater detail herein.
Preferably, the valve element 28 is molded as a unitary piece, typically from a deformable elastomeric material, such as silicone or rubber or Santoprene® thermoplastic, manufactured by Advanced Elastomer Systems, LP of Akron, Ohio. The valve element 28 may be fixedly attached to the inlet 18 by any of a number of means. Suitable means include, but are not limited to, adhesive or mechanical bonding and interference overmolding. At the inlet, the upper seal 30 preferably has a substantially flat or slightly outwardly curved outside surface that can be easily wiped with antiseptic, which aids in preventing contamination during use. The apertures 32 and 42 may be integrally formed, e.g., molded, with the seals 30 and 40 or may be formed after the valve element 28 is manufactured or seated within the inlet 18, such as by a slitting operation.
In use, a male luer 19 is inserted into the inlet 18 through the first aperture 32, which causes deformation of the valve element 28. The valve element 28 continues to deform as the luer is further inserted into the inlet 18 and, in a preferred embodiment, the lower seal portion 40 is adapted to deform and open the second aperture 42 substantially concurrently with full insertion of the male luer for insertion or withdrawal of liquid. To avoid fluid displacement as the luer is inserted into or removed from the inlet 18, upon full insertion of the male luer 19 the distance between the apertures 32 and 42 is preferably greater than the maximum extent to which the luer may be inserted into the inlet 18. By such a configuration, a fully inserted luer will remain almost wholly within the chamber 44. Accordingly, only a small portion of the luer may enter the LAD flow path 22 and decrease the available open volume, so fluid displacement upon insertion and removal of the luer is substantially neutralized.
In one embodiment, the blunt nose tubular portion 36 deforms outwardly by the force of the male luer to be in close proximity of the wall of the inlet 18, which reduces that volume of the LAD 10 as a possible fluid stagnation region or dead zone. While this tends to decrease the volume of the flow path 22, this change in volume is minor, especially compared to prior art valves which cause the luer to be fully inserted into the flow path, so fluid displacement with respect to the outlet 20 during insertion and removal of the luer is insignificant.
The upper seal 112 and umbrella valve 114 are deformable, with the upper seal 112 preferably comprising an elastomeric material having a relatively low durometer, such as silicone or rubber or Santoprene® elastomer, and the umbrella valve 114 comprising a more rigid but still flexible material, such as a relatively high durometer silicone.
The upper seal 112 defines a normally closed resealable aperture or slit 116 adapted to receive a male luer 118. The upper seal 112 preferably conforms generally to the description of the upper seal 30 of the embodiment of
In the illustrated embodiment, the peripheral edge of the umbrella valve 114 seats on an annular shoulder 120 of the housing 102 and is maintained in place by stop means (not illustrated), but it may cooperate with alternative housing features, such as an annular channel or the like. The umbrella valve 114 is movable between a downwardly concave closed condition (
In use, the male luer 118 is initially inserted into the inlet 104 through the aperture 116. The luer 118 is further inserted until it contacts the umbrella valve 114 and moves the umbrella valve 114 to the open condition of
It will be seen that the luer 118 remains above the umbrella valve 114 and outside of the LAD flow path 108 at all times, so the deflection and deformation of the umbrella valve 114 represents the only variation of the flow path 108 volume during insertion and removal of the luer 118. Accordingly, the volume of the flow path 108 remains substantially constant during use of the LAD 100, and fluid displacement upon insertion and removal of the luer 118 is substantially neutralized.
Preferably, the valve element 210 is comprised of a deformable elastomeric material, such as silicone or rubber or Santoprene® material. The valve element 210 may be fixedly attached to the inlet 204 by any of a number of means. Suitable means include, but are not limited to, adhesive or mechanical bonding and interference overmolding. Preferably, the spacer member 216 is not affixed to the inlet 204, and may be separated therefrom by a gap or buffer (not illustrated) to allow outward radial movement and deformation of the spacer member 216.
The spacer member 216 may be composed of a foam 218, and referring particularly to
In use, a male luer is inserted into the inlet 204 through the upper aperture 222, which causes deformation of the valve element 210. With the male luer partially inserted into the cavity 218, the spacer member 216 deforms downwardly and outwardly to contact the inlet wall. This deformation of the spacer member 216 is transmitted in part to the lower seal 214, but the lower seal 214 is preferably adapted such that the lower aperture 224 will not deform and open until the luer is fully inserted into the inlet 204.
In an embodiment, the lower seal 214 is sufficiently spaced from the upper seal 212 so that the luer cannot penetrate the lower aperture 224 and enter the LAD flow path 208. Hence, the lower aperture 224 is adapted to open primarily under influence of the deformable spacer member 216, rather than by primarily contact with the luer. When fluid transfer is complete and the luer is moved away from the inlet 204, the lower aperture 224 closes to minimize flow through the LAD 200 and reflux into the housing. As the valve element 210 is adapted to regulate fluid flow through the LAD 200 while minimizing the volume of the luer entering the LAD flow path 208, it will be appreciated that fluid displacement upon insertion and removal of the luer is substantially neutralized.
A collapsible chamber 316 extends downwardly from the upper seal 312 and communicates with the upper aperture 314. The collapsible chamber 316 includes a collapsible wall 317 and may be comprised of a thermoplastic elastomeric material and includes a normally closed low cracking (opening) pressure bi-directional seal 318 that may be provided in any of a number of configurations. In the embodiment of
Regardless of the particular configuration of the low pressure seal, it is preferably adapted to open at a lower pressure than the upper aperture 314. For example, in the embodiment of
Preferably, a male luer 301 fully inserted into the inlet 304 will be partially received within the chamber 316, but will not extend sufficiently to penetrate the low pressure seal 318 and enter the LAD flow path 308. Accordingly, fluid communication between the LAD inlet 304 and outlet 306 requires a luer 301 inserted into the inlet 304 (to open the upper aperture 314) and fluid flow from the luer or the system associated with the outlet 306 (to open the low pressure seal 318). When fluid flow through the LAD 300 ceases, the low pressure seal 318 will automatically move to a closed condition and the luer may be removed from the inlet 304. The chamber 316 may be treated with a lubricating material to permit easy release of the luer. Alternatively, the inner surface of the chamber 316 may be roughened or textured, as in a pleated bellows (
The lower seal 414 is positioned such that a male luer fully inserted into the LAD inlet 404 will fully penetrate the aperture 416 of the upper seal 412, but only partially penetrate the aperture 418 of the lower seal 414. Preferably, the luer will contact the lower seal 414 and move the lower aperture 418 into an open condition substantially concurrently with full insertion of the luer. This may be preferred for a number of reasons. First, fluid flow through the LAD 400, 400a cannot begin until the luer is fully inserted into the inlet 404 and will cease as soon as the luer is moved away from the inlet 404. Second, by preventing the luer from protruding into the LAD flow path 408, fluid displacement during insertion and removal of the luer is substantially neutralized. Other advantages will be apparent to those of ordinary skill in the art.
The lower seal 514 is a deformable, unitary structure comprised of a head portion 520 and a plurality of legs 522 extending downwardly from the head portion 520. The head portion 520 is sufficiently sized to form an interference fit with the inlet 504 in the closed condition of
The lower seal 614 can be understood as a generally tubular member with cup-shaped portions removed from its upper and lower ends to define an upper void volume 618 and a lower void volume 620. The volumes 618 and 620 are separated by a lower resealable aperture 622 that is movable between a closed condition (
Preferably, the lower seal 614 is substantially comprised of a compressible polymeric foam with a closed-cell structure, such as a silicone or urethane foam. A closed-cell structure is typically more rigid and less compressible than an open-cell structure, so such a configuration may be preferred for ensuring a tight seal immediately before a male luer is fully inserted into the inlet 604 and immediately after the luer is removed therefrom. The lower seal 614 is preferably harder than the upper seal 612 (˜70-80 D vs. ˜40-50 D in one embodiment) to provide a relatively high pressure seal. The foam may also be treated with a lubricant or anti-microbial gel or liquid or any other performance-enhancing material.
In use, a male luer 617 is inserted into the inlet 604 and penetrates the upper aperture 616, thereby deforming the upper seal 612 and moving it partially into the upper void volume 618. The luer is further inserted into the inlet 604 and contacts the lower seal 614. Preferably, the lower seal 614 is positioned such that a fully inserted luer will enter into the lower aperture 622 without moving beyond the aperture 622 and entering the lower void volume 620 or LAD flow path 608. A luer so inserted will compress the lower seal 614 outwardly against the wall of the inlet 604 and open the lower aperture 622 to allow fluid flow through the LAD 600. As the valve element 610 is adapted to regulate fluid flow without allowing the male luer into the LAD flow path 608 or lower void volume 620, fluid displacement upon insertion and removal of the luer is substantially neutralized. The incidence of fluid displacement is even further minimized by the use of a compressible lower seal 614 that compresses outwardly, rather than deforming downwardly, as described previously herein.
Preferably, the valve element 710 is provided as a unitary piece, comprised of a deformable elastomeric material, such as silicone or rubber or Santoprene®. The upper seal 712 may be fixedly attached to the inlet 704 by any of a number of means. Suitable means include, but are not limited to, adhesive or mechanical bonding and interference overmolding.
In use, a male luer 723 is inserted into the inlet 704 and deforms the upper seal 712 to penetrate through the upper aperture 714. The male luer is further inserted into the inlet 704 to deform the barbed void volume arrow 716, thereby moving the barbs 722 against the housing 702 and opening the lower aperture 720. An additional benefit of the barbs 722 is realized during insertion of the luer into the inlet 704. As described previously herein, it may be preferred to cause the tapered portion 718 to contact the housing 702 and create a fluid seal. In comparison to a tapered portion 718 having a substantially smooth outer surface, a tapered portion 718 having a plurality of barbs 722 will minimize the compressive force generated when the lower aperture 720 opens and the barbed void volume arrow 716 is pressed against the inlet 704. Preferably, the valve element 710 is adapted such that a fully inserted luer will open the lower aperture 720 without extending into the flow path 708.
When fluid flow through the LAD 700 is completed, the luer is moved away from the inlet 704. Preferably, the tapered portion 718 is resiliently biased to the closed condition so that it will automatically close the lower aperture 720 when the luer is removed. By regulating fluid flow through the LAD 700 without requiring the luer to enter the LAD flow path 708, fluid displacement during insertion and removal of the luer is substantially neutralized.
The LAD 800 of
A valve element 814 is received within the inlet 804 and comprises an upper seal or septum 816 and a torque-activated valve 818 extending downwardly from the upper seal 816. The upper seal 816 is fixedly attached to the upper housing portion 810 and a lower section of the torque-activated valve 818 is fixedly attached to the lower housing portion 812. Hence, it will be appreciated that rotation of the upper housing portion 810 with respect to the lower housing portion 812 will impart torsion forces to the torque-activated valve 818.
The upper seal 816 defines a resealable aperture 820 in communication with a resealable lumen 822 of the torque-activated valve 818. The torque-activated valve 818 is preferably biased to a closed condition, wherein the lumen 822 is initially closed prior to rotation of the housing portions 810 and 812. When the housing portions 810 and 812 are rotated with respect to each other, the upper end of the torque-activated valve 818 is twisted with respect to the lower end to create a torsion force that opens the lumen 822. The lumen 822 remains open until the upper and lower housing portions 810 and 812 are returned to their original position relative to each other.
In contrast to the lumen 822 of the torque-activated valve 818, the aperture 820 of the upper seal 816 is not opened by rotation of the housing portions 810 and 812, but by insertion of a male luer 821 Accordingly, fluid flow through the LAD 800 cannot be achieved until a luer is inserted into the inlet 804 and the housing portions 810 and 812 are rotated with respect to each other.
A common system for locking a luer onto an LAD is to use mating threads, as described herein with respect to the embodiment of
A valve element 916 is received within the inlet 904 to define a barrier between the flow path 908 and the outside environment. The valve element 916 comprises an upper seal 918 and a resealable over sleeve 920 surrounding the stand pipe 914. The upper seal 918 and over sleeve 920 are deformable, and preferably comprised of an elastomeric material, such as silicone or rubber or Santoprene® material.
The upper seal 918 defines a resealable upper aperture or slit 922 adapted to receive a male luer (not illustrated) and is preferably mechanically fixed within the upper housing portion 910.
The over sleeve 920 defines a lower aperture 924 and is movable between a closed condition (
The upper seal 1012 defines a resealable upper aperture or slit 1016 adapted to receive a male luer (not illustrated) and the sealing flanges 1014 meet at a point to define a resealable lower aperture 1018 movable between a closed condition (
The sealing flanges 1014 may have a generally “dogleg” configuration to define an open chamber 1020 in communication with the upper and lower apertures 1016 and 1018. In the closed condition of
Regardless of the nature of the lower aperture 1016, the valve element 1010 is preferably adapted such that a fully inserted luer will enter into the chamber 1020, but not the LAD flow path 1008. By confining the luer to the chamber 1020, it will not alter the open volume of the LAD flow path 1008, so fluid displacement upon insertion and removal of the luer is substantially neutralized.
A cammed seal cap 1116 is secured to a lower surface of the upper seal 1112 and extends downwardly therefrom. The seal cap 1116 is preferably comprised of a thermoplastic material and defines a lower aperture 1118 movable between a closed condition (
While the present invention has been described in terms of certain preferred and alternative embodiments for purposes of illustration, it is not limited to the precise embodiments shown or to the particular features, shapes or sizes illustrated. A variety of changes may be made without departing from the present invention as defined by the appended claims.
This application claims the benefit of U.S. Provisional Patent Application No. 60/862,502, filed Oct. 23, 2006, entitled “LUER ACTIVATED DEVICE WITH MINIMAL FLUID DISPLACEMENT”, the entire contents of which are hereby incorporated by reference and relied upon.
Number | Name | Date | Kind |
---|---|---|---|
4176588 | Baron | Dec 1979 | A |
4334551 | Pfister | Jun 1982 | A |
4413462 | Rose | Nov 1983 | A |
4475548 | Muto | Oct 1984 | A |
4691929 | Neumaier et al. | Sep 1987 | A |
4928212 | Benavides | May 1990 | A |
4943896 | Johnson | Jul 1990 | A |
4946445 | Lynn | Aug 1990 | A |
4964855 | Todd et al. | Oct 1990 | A |
4973443 | Larson et al. | Nov 1990 | A |
4998713 | Vaillancourt | Mar 1991 | A |
4998927 | Vaillancourt | Mar 1991 | A |
5009490 | Kouno et al. | Apr 1991 | A |
5019325 | Larson et al. | May 1991 | A |
5046456 | Heyman et al. | Sep 1991 | A |
D321250 | Jepson et al. | Oct 1991 | S |
D321251 | Jepson et al. | Oct 1991 | S |
5064416 | Newgard et al. | Nov 1991 | A |
5065783 | Ogle, II | Nov 1991 | A |
5100394 | Dudar et al. | Mar 1992 | A |
5114408 | Fleischhaker et al. | May 1992 | A |
5122123 | Vaillancourt | Jun 1992 | A |
5135489 | Jepson et al. | Aug 1992 | A |
5154703 | Bonaldo | Oct 1992 | A |
5158554 | Jepson et al. | Oct 1992 | A |
5171234 | Jepson et al. | Dec 1992 | A |
5188620 | Jepson et al. | Feb 1993 | A |
5199947 | Lopez et al. | Apr 1993 | A |
5201717 | Wyatt et al. | Apr 1993 | A |
5203775 | Frank et al. | Apr 1993 | A |
5211638 | Dudar et al. | May 1993 | A |
5242393 | Brimhall et al. | Sep 1993 | A |
5242425 | White et al. | Sep 1993 | A |
5242432 | DeFrank | Sep 1993 | A |
5251873 | Atkinson et al. | Oct 1993 | A |
5256155 | Yerlikaya et al. | Oct 1993 | A |
5269763 | Boehmer et al. | Dec 1993 | A |
5269771 | Thomas et al. | Dec 1993 | A |
5280876 | Atkins | Jan 1994 | A |
5290254 | Vaillancourt | Mar 1994 | A |
5295657 | Atkinson | Mar 1994 | A |
5295658 | Atkinson et al. | Mar 1994 | A |
5312377 | Dalton | May 1994 | A |
5323264 | Kato | Jun 1994 | A |
5324270 | Kayan et al. | Jun 1994 | A |
5344414 | Lopez et al. | Sep 1994 | A |
5360413 | Leason et al. | Nov 1994 | A |
5401245 | Haining | Mar 1995 | A |
5402982 | Atkinson et al. | Apr 1995 | A |
5411499 | Dudar et al. | May 1995 | A |
5417673 | Gordon | May 1995 | A |
5470319 | Mayer | Nov 1995 | A |
5487731 | Denton | Jan 1996 | A |
5492147 | Challender et al. | Feb 1996 | A |
5514109 | Mollenauer et al. | May 1996 | A |
5533708 | Atkinson et al. | Jul 1996 | A |
5540661 | Tomisaka et al. | Jul 1996 | A |
5549566 | Elias et al. | Aug 1996 | A |
5549651 | Lynn | Aug 1996 | A |
5556388 | Johlin, Jr. | Sep 1996 | A |
5578059 | Patzer | Nov 1996 | A |
5602016 | Isogai et al. | Feb 1997 | A |
5609584 | Gettig et al. | Mar 1997 | A |
5616129 | Mayer | Apr 1997 | A |
5616130 | Mayer | Apr 1997 | A |
5676346 | Leinsing | Oct 1997 | A |
5677141 | Isogai et al. | Oct 1997 | A |
5685866 | Lopez | Nov 1997 | A |
5690612 | Lopez et al. | Nov 1997 | A |
5695466 | Lopez et al. | Dec 1997 | A |
5699821 | Paradis | Dec 1997 | A |
5700248 | Lopez | Dec 1997 | A |
5730418 | Feith et al. | Mar 1998 | A |
5738663 | Lopez | Apr 1998 | A |
5773272 | Isogai et al. | Jun 1998 | A |
RE35841 | Frank et al. | Jul 1998 | E |
5788675 | Mayer | Aug 1998 | A |
5797897 | Jepson et al. | Aug 1998 | A |
5820601 | Mayer | Oct 1998 | A |
5836923 | Mayer | Nov 1998 | A |
5865807 | Blake, III | Feb 1999 | A |
5873862 | Lopez | Feb 1999 | A |
5901942 | Lopez | May 1999 | A |
5928204 | Lopez | Jul 1999 | A |
5957898 | Jepson et al. | Sep 1999 | A |
5967490 | Pike | Oct 1999 | A |
5971965 | Mayer | Oct 1999 | A |
RE36587 | Tanaka et al. | Feb 2000 | E |
6019748 | Lopez | Feb 2000 | A |
6029946 | Doyle | Feb 2000 | A |
6036171 | Weinheimer et al. | Mar 2000 | A |
6039302 | Cote, Sr. et al. | Mar 2000 | A |
RE36661 | Tanaka et al. | Apr 2000 | E |
6048335 | Mayer | Apr 2000 | A |
6089541 | Weinheimer et al. | Jul 2000 | A |
6113068 | Ryan | Sep 2000 | A |
6132403 | Lopez | Oct 2000 | A |
6132404 | Lopez | Oct 2000 | A |
6146396 | Konya et al. | Nov 2000 | A |
6152900 | Mayer | Nov 2000 | A |
6162251 | Kredovski | Dec 2000 | A |
6171287 | Lynn et al. | Jan 2001 | B1 |
6177037 | Mayer | Jan 2001 | B1 |
6183448 | Mayer | Feb 2001 | B1 |
6187476 | Pyun et al. | Feb 2001 | B1 |
6210624 | Mayer | Apr 2001 | B1 |
6228069 | Barth et al. | May 2001 | B1 |
6245048 | Fangrow, Jr. et al. | Jun 2001 | B1 |
6261268 | Mayer | Jul 2001 | B1 |
6261282 | Jepson et al. | Jul 2001 | B1 |
6290206 | Doyle | Sep 2001 | B1 |
6299132 | Weinheimer et al. | Oct 2001 | B1 |
6325782 | Lopez | Dec 2001 | B1 |
6341802 | Matkovich | Jan 2002 | B1 |
6344033 | Jepson et al. | Feb 2002 | B1 |
6355023 | Roth et al. | Mar 2002 | B1 |
6364869 | Bonaldo | Apr 2002 | B1 |
6374876 | Bynum | Apr 2002 | B2 |
6383168 | Landau et al. | May 2002 | B1 |
6390120 | Guala | May 2002 | B1 |
6390130 | Guala | May 2002 | B1 |
6394983 | Mayoral et al. | May 2002 | B1 |
6394992 | Sjoholm | May 2002 | B1 |
6402723 | Lampropoulos | Jun 2002 | B1 |
6408897 | Laurent et al. | Jun 2002 | B1 |
6409707 | Guala | Jun 2002 | B1 |
6409708 | Wessman | Jun 2002 | B1 |
6423053 | Lee | Jul 2002 | B1 |
6428520 | Lopez et al. | Aug 2002 | B1 |
6440107 | Trombley, III et al. | Aug 2002 | B1 |
6467732 | Tsukahara | Oct 2002 | B2 |
6481756 | Field et al. | Nov 2002 | B1 |
6482188 | Rogers et al. | Nov 2002 | B1 |
6485472 | Richmond | Nov 2002 | B1 |
6486630 | Takagi | Nov 2002 | B2 |
6491668 | Paradis | Dec 2002 | B1 |
6508807 | Peters | Jan 2003 | B1 |
6520932 | Taylor | Feb 2003 | B2 |
6536805 | Matkovich | Mar 2003 | B2 |
6537258 | Guala | Mar 2003 | B1 |
6539248 | Moroski | Mar 2003 | B1 |
6541802 | Doyle | Apr 2003 | B2 |
6543745 | Enerson | Apr 2003 | B1 |
6544236 | Cragg et al. | Apr 2003 | B1 |
6569118 | Johnson et al. | May 2003 | B2 |
6569125 | Jepson et al. | May 2003 | B2 |
RE38145 | Lynn | Jun 2003 | E |
6572590 | Stevens et al. | Jun 2003 | B1 |
6572591 | Mayer | Jun 2003 | B2 |
6572592 | Lopez | Jun 2003 | B1 |
6581906 | Pott et al. | Jun 2003 | B2 |
6585229 | Cote, Sr. et al. | Jul 2003 | B2 |
6595954 | Luther et al. | Jul 2003 | B1 |
6595964 | Finley et al. | Jul 2003 | B2 |
6599273 | Lopez | Jul 2003 | B1 |
6605076 | Jepson et al. | Aug 2003 | B1 |
6609696 | Enerson | Aug 2003 | B2 |
6620119 | Utterberg et al. | Sep 2003 | B1 |
6626418 | Kiehne | Sep 2003 | B2 |
6634033 | Mizuno et al. | Oct 2003 | B2 |
6635044 | Lopez | Oct 2003 | B2 |
6638244 | Reynolds | Oct 2003 | B1 |
6638258 | Schwartz et al. | Oct 2003 | B2 |
6651956 | Miller | Nov 2003 | B2 |
6655655 | Matkovich et al. | Dec 2003 | B1 |
6666839 | Utterberg et al. | Dec 2003 | B2 |
6669673 | Lopez | Dec 2003 | B2 |
6669681 | Jepson et al. | Dec 2003 | B2 |
6673059 | Guala | Jan 2004 | B2 |
6679529 | Johnson et al. | Jan 2004 | B2 |
6681810 | Weston | Jan 2004 | B2 |
6682509 | Lopez | Jan 2004 | B2 |
6695817 | Fangrow, Jr. | Feb 2004 | B1 |
6699222 | Jones et al. | Mar 2004 | B1 |
6706022 | Leinsing et al. | Mar 2004 | B1 |
6716187 | Jorgensen et al. | Apr 2004 | B1 |
6716189 | Jarvik et al. | Apr 2004 | B1 |
6722705 | Korkor | Apr 2004 | B2 |
6723074 | Halseth | Apr 2004 | B1 |
6726651 | Robinson et al. | Apr 2004 | B1 |
6726672 | Hanly et al. | Apr 2004 | B1 |
6730883 | Brown et al. | May 2004 | B2 |
6745998 | Doyle | Jun 2004 | B2 |
6746438 | Arnissolle | Jun 2004 | B1 |
6755391 | Newton et al. | Jun 2004 | B2 |
6758833 | Lopez | Jul 2004 | B2 |
6770051 | Hughes et al. | Aug 2004 | B2 |
6802490 | Leinsing et al. | Oct 2004 | B2 |
6802836 | Bouphavichith et al. | Oct 2004 | B2 |
6808161 | Hishikawa | Oct 2004 | B1 |
6808509 | Davey | Oct 2004 | B1 |
6811139 | Hishikawa | Nov 2004 | B2 |
6814726 | Lauer | Nov 2004 | B1 |
6827709 | Fujii | Dec 2004 | B2 |
6827710 | Mooney et al. | Dec 2004 | B1 |
6834842 | Houde | Dec 2004 | B2 |
6840501 | Doyle | Jan 2005 | B2 |
6843513 | Guala | Jan 2005 | B2 |
6866656 | Tingey et al. | Mar 2005 | B2 |
6869426 | Ganem | Mar 2005 | B2 |
6871087 | Hughes et al. | Mar 2005 | B1 |
6874522 | Anderson et al. | Apr 2005 | B2 |
6878905 | Brown et al. | Apr 2005 | B2 |
6880801 | Matkovich et al. | Apr 2005 | B2 |
6883778 | Newton et al. | Apr 2005 | B1 |
6893056 | Guala | May 2005 | B2 |
6902207 | Lickliter | Jun 2005 | B2 |
6908459 | Harding et al. | Jun 2005 | B2 |
6911025 | Miyahara | Jun 2005 | B2 |
6916309 | Fangrow, Jr. | Jul 2005 | B2 |
6918500 | Okiyama | Jul 2005 | B2 |
6932795 | Lopez et al. | Aug 2005 | B2 |
6953450 | Baldwin et al. | Oct 2005 | B2 |
6955669 | Curutcharry | Oct 2005 | B2 |
6960198 | Sarmiento | Nov 2005 | B2 |
6964406 | Doyle | Nov 2005 | B2 |
6969381 | Voorhees | Nov 2005 | B2 |
6972001 | Emig et al. | Dec 2005 | B2 |
6974446 | Hommann et al. | Dec 2005 | B2 |
6994315 | Ryan et al. | Feb 2006 | B2 |
7004934 | Vaillancourt | Feb 2006 | B2 |
7008406 | Mayer | Mar 2006 | B2 |
7014169 | Newton et al. | Mar 2006 | B2 |
7025744 | Utterberg et al. | Apr 2006 | B2 |
7033339 | Lynn | Apr 2006 | B1 |
7037302 | Vaillancourt et al. | May 2006 | B2 |
7041087 | Henderson et al. | May 2006 | B2 |
7044441 | Doyle | May 2006 | B2 |
7044937 | Kirwan et al. | May 2006 | B1 |
7081600 | Brown et al. | Jul 2006 | B2 |
7083605 | Miyahara | Aug 2006 | B2 |
7090191 | Matkovich et al. | Aug 2006 | B2 |
7097209 | Sparrman et al. | Aug 2006 | B2 |
7100891 | Doyle | Sep 2006 | B2 |
7104520 | Leinsing et al. | Sep 2006 | B2 |
RE39334 | Lynn | Oct 2006 | E |
7114701 | Peppel | Oct 2006 | B2 |
7118560 | Bonaldo | Oct 2006 | B2 |
7128348 | Kawamura et al. | Oct 2006 | B2 |
7137974 | Almasian et al. | Nov 2006 | B2 |
7140592 | Phillips | Nov 2006 | B2 |
7153296 | Mitchell | Dec 2006 | B2 |
7156826 | Ishii et al. | Jan 2007 | B2 |
7160272 | Eyal et al. | Jan 2007 | B1 |
RE39499 | Racz | Feb 2007 | E |
7172572 | Diamond et al. | Feb 2007 | B2 |
7174923 | Schorn et al. | Feb 2007 | B2 |
7175615 | Hanly et al. | Feb 2007 | B2 |
7182313 | Doyle | Feb 2007 | B2 |
7184825 | Leinsing et al. | Feb 2007 | B2 |
20010045539 | Doyle | Nov 2001 | A1 |
20010049508 | Fangrow et al. | Dec 2001 | A1 |
20010051791 | Azzolini | Dec 2001 | A1 |
20010051793 | Weston | Dec 2001 | A1 |
20020007157 | Azzolini | Jan 2002 | A1 |
20020024036 | Rohrbough et al. | Feb 2002 | A1 |
20020032433 | Lopez | Mar 2002 | A1 |
20020038114 | Segura | Mar 2002 | A1 |
20020062106 | Chu et al. | May 2002 | A1 |
20020082586 | Finley et al. | Jun 2002 | A1 |
20020099360 | Bierman | Jul 2002 | A1 |
20020108614 | Schultz | Aug 2002 | A1 |
20020115981 | Wessman | Aug 2002 | A1 |
20020115984 | Guala | Aug 2002 | A1 |
20020117645 | Kiehne | Aug 2002 | A1 |
20020128595 | Weston et al. | Sep 2002 | A1 |
20020128607 | Haury et al. | Sep 2002 | A1 |
20020133124 | Leinsing et al. | Sep 2002 | A1 |
20020138047 | Lopez | Sep 2002 | A1 |
20020143300 | Trombley et al. | Oct 2002 | A1 |
20020143301 | Lopez | Oct 2002 | A1 |
20020147429 | Cowan et al. | Oct 2002 | A1 |
20020147431 | Lopez et al. | Oct 2002 | A1 |
20020153503 | Newton et al. | Oct 2002 | A1 |
20020156431 | Feith et al. | Oct 2002 | A1 |
20020161334 | Castellano et al. | Oct 2002 | A1 |
20020193752 | Lynn | Dec 2002 | A1 |
20030028156 | Juliar | Feb 2003 | A1 |
20030032940 | Doyle | Feb 2003 | A1 |
20030036735 | Jepson et al. | Feb 2003 | A1 |
20030050610 | Newton et al. | Mar 2003 | A1 |
20030060779 | Richmond | Mar 2003 | A1 |
20030060804 | Vaillancourt | Mar 2003 | A1 |
20030066978 | Enerson | Apr 2003 | A1 |
20030066980 | Hishikawa | Apr 2003 | A1 |
20030085372 | Newton | May 2003 | A1 |
20030093061 | Ganem | May 2003 | A1 |
20030098430 | Leinsing et al. | May 2003 | A1 |
20030105452 | Mayer | Jun 2003 | A1 |
20030109853 | Harding et al. | Jun 2003 | A1 |
20030120221 | Vaillancourt | Jun 2003 | A1 |
20030127620 | Houde | Jul 2003 | A1 |
20030141477 | Miller | Jul 2003 | A1 |
20030144626 | Hanson et al. | Jul 2003 | A1 |
20030144647 | Miyahara | Jul 2003 | A1 |
20030181850 | Diamond et al. | Sep 2003 | A1 |
20030181854 | Sauvageau | Sep 2003 | A1 |
20030183795 | Doyle | Oct 2003 | A1 |
20030195478 | Russo | Oct 2003 | A1 |
20030199835 | Leinsing et al. | Oct 2003 | A1 |
20030208165 | Christensen et al. | Nov 2003 | A1 |
20030209681 | Leinsing et al. | Nov 2003 | A1 |
20030216712 | Kessler et al. | Nov 2003 | A1 |
20030225379 | Schaffer et al. | Dec 2003 | A1 |
20030236497 | Fremming et al. | Dec 2003 | A1 |
20040006330 | Fangrow | Jan 2004 | A1 |
20040019344 | Peterson et al. | Jan 2004 | A1 |
20040030321 | Fangrow | Feb 2004 | A1 |
20040068238 | Utterberg et al. | Apr 2004 | A1 |
20040068239 | Utterberg | Apr 2004 | A1 |
20040073174 | Lopez | Apr 2004 | A1 |
20040073176 | Utterberg | Apr 2004 | A1 |
20040092886 | Mayer | May 2004 | A1 |
20040102738 | Dikeman et al. | May 2004 | A1 |
20040111078 | Miyahara | Jun 2004 | A1 |
20040116869 | Heinz et al. | Jun 2004 | A1 |
20040122418 | Voorhees | Jun 2004 | A1 |
20040124388 | Kiehne | Jul 2004 | A1 |
20040124389 | Phillips | Jul 2004 | A1 |
20040138641 | Patzer | Jul 2004 | A1 |
20040162517 | Furst et al. | Aug 2004 | A1 |
20040162540 | Walenciak et al. | Aug 2004 | A1 |
20040171993 | Bonaldo | Sep 2004 | A1 |
20040172006 | Bonaldo | Sep 2004 | A1 |
20040186458 | Hiejima et al. | Sep 2004 | A1 |
20040193119 | Canaud et al. | Sep 2004 | A1 |
20040199126 | Harding et al. | Oct 2004 | A1 |
20040204699 | Hanly et al. | Oct 2004 | A1 |
20040206924 | Newton et al. | Oct 2004 | A1 |
20040210194 | Bonnette et al. | Oct 2004 | A1 |
20040225274 | Jansen et al. | Nov 2004 | A1 |
20040227120 | Raybuck | Nov 2004 | A1 |
20040236314 | Saab | Nov 2004 | A1 |
20040243065 | McConnell et al. | Dec 2004 | A1 |
20040243069 | Feith et al. | Dec 2004 | A1 |
20040243070 | Lopez | Dec 2004 | A1 |
20040249349 | Wentling | Dec 2004 | A1 |
20040254534 | Bjorkman et al. | Dec 2004 | A1 |
20040260243 | Rickerd | Dec 2004 | A1 |
20040260266 | Cuschieri et al. | Dec 2004 | A1 |
20050010168 | Kendall | Jan 2005 | A1 |
20050015070 | Delnevo et al. | Jan 2005 | A1 |
20050021000 | Adair et al. | Jan 2005 | A1 |
20050033267 | Decaria | Feb 2005 | A1 |
20050033268 | Decaria | Feb 2005 | A1 |
20050033269 | Decaria | Feb 2005 | A1 |
20050038397 | Newton et al. | Feb 2005 | A1 |
20050059952 | Giuliano et al. | Mar 2005 | A1 |
20050087715 | Doyle | Apr 2005 | A1 |
20050090805 | Shaw et al. | Apr 2005 | A1 |
20050096585 | Schon et al. | May 2005 | A1 |
20050107770 | Schweikert et al. | May 2005 | A1 |
20050119613 | Moenning et al. | Jun 2005 | A1 |
20050121638 | Doyle | Jun 2005 | A1 |
20050124935 | McMichael | Jun 2005 | A1 |
20050124942 | Richmond | Jun 2005 | A1 |
20050124943 | Yang | Jun 2005 | A1 |
20050154372 | Minezaki | Jul 2005 | A1 |
20050159710 | Utterberg | Jul 2005 | A1 |
20050165365 | Newton et al. | Jul 2005 | A1 |
20050171487 | Haury et al. | Aug 2005 | A1 |
20050209555 | Middleton et al. | Sep 2005 | A1 |
20050228362 | Vaillancourt | Oct 2005 | A1 |
20050256460 | Rome et al. | Nov 2005 | A1 |
20050256461 | DiFiore et al. | Nov 2005 | A1 |
20050261637 | Miller | Nov 2005 | A1 |
20050261665 | Voorhees | Nov 2005 | A1 |
20050267445 | Mendels | Dec 2005 | A1 |
20060015086 | Rasmussen et al. | Jan 2006 | A1 |
20060025724 | Chen | Feb 2006 | A1 |
20060025751 | Roy et al. | Feb 2006 | A1 |
20060027270 | Truitt et al. | Feb 2006 | A1 |
20060047251 | Bickford-Smith et al. | Mar 2006 | A1 |
20060074386 | Wollmann | Apr 2006 | A1 |
20060089603 | Truitt et al. | Apr 2006 | A1 |
20060089604 | Guerrero | Apr 2006 | A1 |
20060089605 | Fitzgerald | Apr 2006 | A1 |
20060111694 | Fukai et al. | May 2006 | A1 |
20060129109 | Shaw et al. | Jun 2006 | A1 |
20060129112 | Lynn | Jun 2006 | A1 |
20060142735 | Whitley | Jun 2006 | A1 |
20060149213 | Raybuck | Jul 2006 | A1 |
20060161115 | Fangrow | Jul 2006 | A1 |
20060173420 | Fangrow | Aug 2006 | A1 |
20060178645 | Peppel | Aug 2006 | A1 |
20060184139 | Quigley et al. | Aug 2006 | A1 |
20060184140 | Okiyama | Aug 2006 | A1 |
20060200072 | Peppel | Sep 2006 | A1 |
20060200095 | Steube | Sep 2006 | A1 |
20060200096 | Fangrow | Sep 2006 | A1 |
20060206058 | Lopez | Sep 2006 | A1 |
20060206059 | Lopez | Sep 2006 | A1 |
20060211997 | Fangrow | Sep 2006 | A1 |
20060211998 | Fangrow | Sep 2006 | A1 |
20060211999 | Fangrow | Sep 2006 | A1 |
20060212000 | Fangrow | Sep 2006 | A1 |
20060212001 | Fangrow | Sep 2006 | A1 |
20060212002 | Fangrow | Sep 2006 | A1 |
20060212003 | Fangrow | Sep 2006 | A1 |
20060212005 | Fangrow | Sep 2006 | A1 |
20060212006 | Fangrow et al. | Sep 2006 | A1 |
20060217671 | Peppel | Sep 2006 | A1 |
20060217679 | Hanly et al. | Sep 2006 | A1 |
20060217683 | Patania | Sep 2006 | A1 |
20060229571 | Peppel | Oct 2006 | A1 |
20060229590 | Roy | Oct 2006 | A1 |
20060264842 | Fangrow | Nov 2006 | A1 |
20060264843 | Fangrow | Nov 2006 | A1 |
20060264844 | Fangrow | Nov 2006 | A1 |
20060264845 | Lopez | Nov 2006 | A1 |
20060264846 | Lopez | Nov 2006 | A1 |
20060264847 | Lopez | Nov 2006 | A1 |
20060264848 | Fangrow | Nov 2006 | A1 |
20060264890 | Moberg et al. | Nov 2006 | A1 |
20060264891 | Lopez | Nov 2006 | A1 |
20060264892 | Lopez | Nov 2006 | A1 |
20060264894 | Moberg et al. | Nov 2006 | A1 |
20060264908 | Ishii et al. | Nov 2006 | A1 |
20060264909 | Fangrow | Nov 2006 | A1 |
20060264910 | Fangrow | Nov 2006 | A1 |
20060270999 | Fangrow | Nov 2006 | A1 |
20060271012 | Canoud | Nov 2006 | A1 |
20060271015 | Mantell | Nov 2006 | A1 |
20060271016 | Fangrow | Nov 2006 | A1 |
20060276757 | Fangrow | Dec 2006 | A1 |
20060276758 | Fangrow | Dec 2006 | A1 |
20060287638 | Aneas | Dec 2006 | A1 |
20060287639 | Sharp | Dec 2006 | A1 |
20060293629 | Cote et al. | Dec 2006 | A1 |
20060293640 | Greco | Dec 2006 | A1 |
20070032775 | Niedospial et al. | Feb 2007 | A1 |
20070032776 | Skinner et al. | Feb 2007 | A1 |
20070038189 | Bartholomew | Feb 2007 | A1 |
20070043334 | Guala | Feb 2007 | A1 |
20070060898 | Shaughnessy et al. | Mar 2007 | A1 |
20070060902 | Brandenburger et al. | Mar 2007 | A1 |
20070060904 | Vedrine et al. | Mar 2007 | A1 |
20070073242 | Andersen et al. | Mar 2007 | A1 |
20070078393 | Lynch et al. | Apr 2007 | A1 |
20070078429 | Sharp | Apr 2007 | A1 |
20070083157 | Belley et al. | Apr 2007 | A1 |
20070088252 | Pestotnik et al. | Apr 2007 | A1 |
20070088292 | Fangrow | Apr 2007 | A1 |
20070088293 | Fangrow | Apr 2007 | A1 |
20070088294 | Fangrow | Apr 2007 | A1 |
20070088313 | Zinger et al. | Apr 2007 | A1 |
20070088324 | Fangrow | Apr 2007 | A1 |
20070088325 | Fangrow | Apr 2007 | A1 |
20070088327 | Guala | Apr 2007 | A1 |
20070093764 | Guererro | Apr 2007 | A1 |
20070100294 | Sugita et al. | May 2007 | A1 |
20070112311 | Harding et al. | May 2007 | A1 |
20070112312 | Fangrow | May 2007 | A1 |
20070112313 | Fangrow | May 2007 | A1 |
20070112314 | Harding et al. | May 2007 | A1 |
20070112332 | Harding et al. | May 2007 | A1 |
20070112333 | Hoang et al. | May 2007 | A1 |
20070129705 | Trombley et al. | Jun 2007 | A1 |
20070156112 | Walsh | Jul 2007 | A1 |
20070156118 | Ramsey et al. | Jul 2007 | A1 |
Number | Date | Country |
---|---|---|
1105959 | Jul 1981 | CA |
855319 | Nov 1952 | DE |
8425197 | Oct 1985 | DE |
3740269 | Jun 1989 | DE |
0114677 | Aug 1984 | EP |
0237321 | Sep 1987 | EP |
0309771 | Apr 1989 | EP |
0367549 | Oct 1989 | EP |
0399119 | Nov 1990 | EP |
0438909 | Dec 1990 | EP |
0446463 | Dec 1990 | EP |
1733749 | Dec 2006 | EP |
2034185 | Jun 1980 | GB |
8601712 | Mar 1986 | WO |
8603416 | Jun 1986 | WO |
9311828 | Jun 1993 | WO |
9721463 | Jun 1997 | WO |
9721464 | Jun 1997 | WO |
9826835 | Jun 1998 | WO |
9958186 | Nov 1999 | WO |
0204065 | Jan 2002 | WO |
03086528 | Oct 2003 | WO |
Number | Date | Country | |
---|---|---|---|
20080093571 A1 | Apr 2008 | US |
Number | Date | Country | |
---|---|---|---|
60862502 | Oct 2006 | US |